Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > The reason no analysts took Thera seriously

<< Previous

Bullboard Posts

Next >>

Comment by JayjayUSA12007on Apr 15, 2021 1:00am

158 Views

Post# 32998673

RE:RE:The reason no analysts took Thera seriously

No disrespect to Canadian companies, or Canada in general.
Just stating a fact regarding Wall Street mentality.

Now, after today's financial report, anybody thinks it would alter the prospect of a successful Phase 1 anti-cancer platform, or NASH Phase 3 ?
Would anyone be suprised that Thera reported a loss, or sales drop in a middle of a pandemic (given the method of Egrifta and Trogarzo treatment) ?
Did anyone expect Thera would report profits or even break-even ?

If not, then what's the surprise ? Why the PPS drop ?

<< Previous

Bullboard Posts

Next >>

Eminent acquires promising Nevada gold project